Chances and risks of anti-VEGF therapy;Chancen und risiken der anti-VEGF-therapie

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 9, 2008, Pages 770-778

  Ziemssen, Focke ^a   Heiduschka, P ^b   Peters, S ^a   Grisanti, S ^c   Schraermeyer, U ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Klinik für Augenheilkunde ^*  (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Bevacizumab (Avastin); Retina; Side effects; Stroke; Thromboembolism; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; RANIBIZUMAB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BLOOD VESSEL DIAMETER; BLOOD VESSEL TONE; CAPILLARY; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CELL SECRETION; CELL SURVIVAL; CHOROID CAPILLARY LAYER; DRUG PENETRATION; DRUG SAFETY; EXON; FILTRATION; HEMATOPOIESIS; HEMODYNAMICS; HUMAN; IMMUNE SYSTEM; INTRON; ISCHEMIA; MEMBRANE FORMATION; MICROANGIOPATHY; NEUROPROTECTION; NONHUMAN; OXYGEN SUPPLY; PERICYTE; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; RISK FACTOR; TREATMENT RESPONSE; VASODILATATION; VISUAL FIELD;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54749109904     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027487     Document Type: Review

References (133)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186
2. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985
3. Adamis AP, Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71
4. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676
5. Geitzenauer W, Michels S, Prager F et al. Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2006; 223: 822-827
6. Roskoski RJr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007; 62: 179-213
7. Liu L, Simon MC. Regulation of transcription and translation by hypoxia. Cancer Biol Ther 2004; 3: 492-497
8. Liu K, Yang Y, Mansbridge J. Comparison of the stress response to cryopreservation in monolayer and three-dimensional human fibroblast cultures: stress proteins, MAP kinases, and growth factor gene expression. Tissue Eng 2000; 6: 539-554
9. Kucab JE, Dunn SE. Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis 2003; 17: 41-47
10. Cohen T, Nahari D, Cerem LW et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736-741
11. Stocks J, Bradbury D, Corbett L et al. Cytokines upregulate vascular endothelial growth factor secretion by human airway smooth muscle cells: Role of endogenous prostanoids. FEBS Lett 2005; 579: 2551-2556
12. Finkenzeller G, Marme D, Weich HA et al. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res 1992; 52: 4821-4823
13. Ryuto M, Ono M, Izumi H et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996; 271: 28220-28228
14. Pertovaara L, Kaipainen A, Mustonen T et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994; 269: 6271-6274
15. Carnesecchi S, Carpentier JL, Foti M et al. Insulin-induced vascular endothelial growth factor expression is mediated by the NADPH oxidase NOX3. Exp Cell Res 2006; 312: 3413-3424
16. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998; 58: 392-395
17. Haggstrom S, Lissbrant IF, Bergh A et al. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161: 1620-1625
18. Wang J, Luo F, Lu JJ et al. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 2002; 97: 163-167
19. Shi BM, Wang XY, Mu QL et al. Expressions of vascular endothelial growth factor in cirrhotic tissues and their relations to proto-oncogene c-fos, c-myc. Hepatobiliary Pancreat Dis Int 2002; 1: 388-391
20. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-45780
21. Ravi R, Mookerjee B, Bhujwalla ZM et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha. Genes Dev 2000; 14: 34-44
22. Bautz F, Rafii S, Kanz L et al. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. Exp Hematol 2000; 28: 700-706
23. Tolosa L, Mir M, Asensio VJ et al. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem 2008; 105: 1080-1090
24. Boer K, Troost D, Spliet WG et al. Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB. Acta Neuropathol 2008; E-Pub
25. Nakamura K, Zen Y, Sato Y et al. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1 alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol 2007; 38: 1532-1546
26. Compernolle V, Brusselmans K, Acker T et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002; 8: 702-710
27. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-3343
28. Clauss M, Weich H, Breier G et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activitiesüüImplications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629-17634
29. Duyndam MC, Hilhorst MC, Schluper HM et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 2002; 160: 537-548
30. Norrby K. Mast cells and angiogenesis. APMIS 2002; 110: 355-371
31. Feistritzer C, Kaneider NC, Sturn DH et al. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am J Respir Cell Mol Biol 2004; 30: 729-735
32. de Paulis A, Prevete N, Fiorentino I et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006; 177: 7322-7331
33. Casella I, Feccia T, Chelucci C et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 2003; 101: 1316-1323
34. Gerber HP, Malik AK, Solar GP et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958
35. Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 2004; 316: 573-579
36. Shui YB, Wang X, Hu JS et al. Vascular endothelial growth factor expression and signaling in the lens. Invest Ophthalmol Vis Sci 2003; 44: 3911-9
37. Yoeruek E, Spitzer MS, Tatar O et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007; 26: 977-982
38. Yang X, Cepko CL. Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells. J Neurosci 1996; 16: 6089-6099
39. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 2007; 85: 762-771
40. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 2006; 47: 3135-3142
41. Smith CP, Steinle JJ. Changes in growth factor expression in normal aging of the rat retina. Exp Eye Res 2007; 85: 817-824
42. Boyd SR, Tan D, Bunce C et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 2002; 86: 448-452
43. Gille J. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 2006; 15: 175-186
44. Bates DO. The chronic effect of vascular endothelial growth factor on individually perfused frog mesenteric microvessels. J Physiol 1998; 513 (Pt 1): 225-233
45. Nagy JA, Benjamin L, Zeng H et al. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008; E-Pub
46. Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002; 8: 294-301
47. Völcker M, Peters S, Inhoffen W et al. Early antiexudative response - OCT monitoring after intravitreal bevacizumab injection]. Ophthalmologe 2006; 103: 476-483
48. Spitzer MS, Ziemssen F, Yoeruek E et al. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008; 34: 70-75
49. Ziemssen F, Deuter CM, Stuebiger N et al. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007; 245: 917-918
50. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007; 13: 2825-2830
51. Clauss M, Gerlach M, Gerlach H et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-1545
52. Min JK, Lee YM, Kim JH et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 2005; 96: 300-307
53. Yoo SA, Bae DG, Ryoo JW et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J Immunol 2005; 174: 5846-5855
54. Hattori K, Dias S, Heissig B et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193: 1005-1014
55. Reinders ME, Sho M, Izawa A et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112: 1655-1665
56. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004; 172: 4618-4623
57. Proescholdt MA, Jacobson S, Tresser N et al. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 2002; 61: 914-925
58. Watanabe H, Mamelak AJ, Wang B et al. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Exp Dermatol 2004; 13: 671-681
59. Halin C, Tobler NE, Vigl B et al. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood 2007; 110: 3158-3167
60. Bock F, Onderka J, Dietrich T et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545-2552
61. Ziemssen F, Warga M, Neuhann IM et al. Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function? Br J Ophthalmol 2006; 90: 922
62. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-1117
63. Behzadian MA, Windsor LJ, Ghaly N et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003; 17: 752-754
64. Lee KS, Park SJ, Kim SR et al. Inhibition of VEGF blocks TGF-{beta}1 production through a PI3K/Akt signalling pathway. Eur Respir J 2008; 31: 523-531
65. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210
66. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest 2007; 117: 576-586
67. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 2007; 39: 121-122
68. Yoeruek E, Ziemssen F, Henke-Fahle S et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol Scand 2007; E-Pub
69. Hsieh MY, Chen WY, Jiang MJ et al. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006; 7: 234-242
70. Hartlapp I, Abe R, Saeed RW et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001; 15: 2215-2224
71. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180
72. Ko J, Ross J, Awad H et al. The effects of ZD 6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res 2005; 129: 251-259
73. Street J, Bao M, deGuzman L et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002; 99: 9656-9661
74. Mac GF, Ji JW, Popel AS. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J Appl Physiol 2007; 102: 722-734
75. Wei W, Chen ZW, Yang Q et al. Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery. Vascul Pharmacol 2007; 46: 253-259
76. Vang R, Thomas GR, Bunting S et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27: 838-844
77. Lin MI, Sessa WC. Vascular endothelial growth factor signaling to endothelial nitric oxide synthase: more than a FLeeTing moment. Circ Res 2006; 99: 666-668
78. Genentech Inc. Avastin™ (bevacizumab) for intravenous use [Package insert]. South San Francisco CA, 2004
79. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
80. Zhu X, Shenhong W, Dahut WL et al. Risks of Proteinuria and Hypertension with Bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193
81. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005; 14: 207-221
82. Kilic U, Kilic E, Jarve A et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 2006; 26: 12439-12446
83. Schiera G, Proia P, Alberti C et al. Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles. J Cell Mol Med 2007; 11: 1384-1394
84. Schanzer A, Wachs FP, Wilhelm D et al. Direct Stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 2004; 14: 237-248
85. Famiglietti EV, Stopa EG, McGookin ED et al. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res 2003; 969: 195-204
86. Nishijima K, Ng YS, Zhong L et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53-67
87. Eremina V, Cui S, Gerber H et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735
88. Kasahara Y, Tuder RM, Taraseviciene-Stewart L et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000; 106: 1311-1319
89. Tuder RM, Zhen L, Cho CY et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88-97
90. Advani A, Kelly DJ, Advani SL et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 2007; 104: 14448-14453
91. Ostendorf T, Kunter U, Eitner F et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999; 104: 913-923
92. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-136
93. Wang JF, Milosveski V, Schramek C et al. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998; 157: 5-12
94. Lammert E, Gu G, McLaughlin M et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 2003; 13: 1070-1074
95. Kamba T, Tam BY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290: H560-H576
96. Inoue M, Hager JH, Ferrara N et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002; 1: 193-202
97. Maharaj AS, Walshe TE, Saint-Geniez M et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008; 205: 491-501
98. Gerber HP, Hillan KJ, Ryan AM et al. VEGF is required for growth and survival in neonatal mice. Development 1999; 126: 1149-1159
99. Hetland ML, Christensen IJ, Lottenburger T et al. Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers 2008; 24: 1-10
100. Iacobellis G, Cipriani R, Gabriele A et al. High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic hypertensive patients. Cytokine 2004; 27: 25-30
101. Csaky KG, Gordiyenko N, Rabena MG et al. Pharmakokinetics of intravitreal bevacizumab in humans. Invest Ophth Vis Sci 2007; 48: A4936
102. Heiduschka P, Fietz H, Hofmeister S et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823
103. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-1615
104. Rodrigues EB, Shiroma H, Meyer CH et al. Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007; 85: 915-916
105. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007; 356: 748-749
106. Verheul HM, Lolkema MP, Qian DZ et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007; 13: 5341-5347
107. Ziemssen F, Zhu Q, Peters S et al. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: Preliminary findings of a pilot study. Int Ophthalmol 2008; E-Pub
108. Ziemssen F, Folprecht G, Ziemssen T. Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'? Acta Ophthalmol Scand 2007; 85: 573-574
109. McGimpsey SJ, Gillies MC. Treatment of macular degeneration - controversy and hope. Br J Ophthalmol 2008; 92: 436-437
110. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354: 980-982
111. Ziemssen F, Grisanti S, Bartz-Schmidt KU. The international intravitreal bevacizumab safety survey. Br J Ophthalmol 2006; 90: 1440-1441
112. Kim I, Ryan AM, Rohan R et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40: 2115-2121
113. Blaauwgeers HG, Holtkamp GM, Rutten H et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155: 421-428
114. Kaempf S, Johnen S, Salz AK et al. Effects of Bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 2008; E-Pub
115. Lüke M, Warga M, Ziemssen F et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90: 1178-1182
116. Peters S, Heiduschka P, Julien S et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002
117. Inai T, Mancuso M, Hashizume H et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52
118. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621
119. Geisen P, Peterson LJ, Martiniuk D et al. Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 2008; 14: 345-357
120. Soliman W, Vinten M, Sander B et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol Scand 2007; E-Pub
121. Baffert F, Le T, Sennino B et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290: H547-H559
122. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349
123. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87
124. Shima C, Sakaguchi H, Gomi F et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007; E-Pub
125. Helotera H, Alitalo K. The VEGF family, the inside story. Cell 2007; 130: 591-592
126. Gruchala M, Roy H, Bhardwaj S et al. Gene therapy for cardiovascular diseases. Curr Pharm Des 2004; 10: 407-423
127. Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383-394
128. Nicoletti JN, Shah SK, McCloskey DP et al. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience 2008; 151: 232-241
129. Karkkainen MJ, Saaristo A, Jussila L et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A 2001; 98: 12677-12682
130. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
131. Celletti FL, Waugh JM, Amabile PG et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-429
132. Detmar M, Brown LF, Claffey KP et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141-1146
133. Yano K, Liaw PC, Mullington JM et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006; 203: 1447-1458